Thailand uses the ASEAN Common Submission Dossier Template (CSDT). An existing ASEAN technical file is a starting point, but product identification, intended use, risk management, clinical or performance evidence and labeling must be checked again against the scope of the Thai application. When filing a detailed listing or license with a full CSDT, the FDA's published worked examples are the reference, and long submission PDFs must be bookmarked.
The Declaration of Conformity (DoC) is prepared by the product owner or the actual manufacturer, must be in English and uses Thai FDA's DoC form; the risk class on it must match the Thai class. The letter of authorisation also uses the Thai FDA form. The IFU sits inside the dossier: the regulations list the label and IFU among the filing documents, so they are reviewed together with the technical file.
Using an existing approval. Thai FDA recognises assessments by eight foreign bodies: US FDA, EU notified bodies, Australia's TGA, Health Canada, Japan's MHLW, WHO prequalification of IVDs, and, under their reliance programmes with Thai FDA, Singapore's HSA and Malaysia's MDA. The route is voluntary and covers Class 2–4 only. The product must not have been approved through an evaluation-exempt route, approvals from the first six bodies must be at least a year old, and the intended use, indications, labeling, IFU and packaging filed in Thailand must be the same as those approved abroad. It changes how the dossier is evaluated; it does not replace the Thai review.